This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Breast cancer accounts for almost 30$ of new cancer diagnoses and is one of the leading causes of cancer deaths in developed
countries. Lumpectomy is a common procedure to remove breast tumors resulting in a tissue void. There are currently
no highly regarded surgical techniques to repair these voids. The objective of this project is to develop an injectable tissue
regeneration matrix with anti-cancer properties. Collagen type I is a common tissue-engineering scaffold due to its intrinsically
bioactive and biodegradable qualities. Collagen is a naturally derived material and, when not cross-linked, is enzymatically
degraded. Research efforts targeting the potential of natural compounds in the fight against cancer are growing. Tannic acid
(TA) belongs to the class of hydrolysable tannins and is found in numerous plants and foods. TA functions as a collagen
crosslinking agent through both hydrogen bonding and hydrophobic effects; thus, as cross-linked collagen is remodeled TA is
released. If used as a biomaterial for tissue-engineering purposes, TA-cross-linked collaged type I would not only serve as an
attachment scaffold for cells but also function as an extended release anti-cancer treatment. When normal adipocytes attach
and grow on TA-cross-linked collagen type I beads the released TA induces apoptosis in ER+ and HER2+ breast cancer cells
with minimal impact on normal breast epithelial cells and adipocytes. The TA-induced apoptosis is mediated by caspases 3, 7
and 9. In conclusion, TA-cross-linked collagen beads show promise as a potential tissue regeneration matrix while providing
an anti-cancer effect.
Brian W Booth completed his PhD at North Carolina State University and Post-doctoral studies at the National Cancer Institute/National Institutes of Health. He joined the Institute for Biological Interfaces of Engineering at Clemson University in 2009 and the Department of Bioengineering in 2015. He has published over 30 peer-reviewed articles and chapters.